Serum brain-derived neurotrophic factor levels in patients with major depression: Effects of antidepressants

Huang, Tiao‐Lai; Lee, Chien-Te; Liu, Yuli

doi:10.1016/j.jpsychires.2007.05.007

Cited by 143 publications

(105 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients did not have significant comorbid medical conditions. Mood symptoms were assessed with the Young Mania Rating Scale (YMRS) 20 and the Hamilton Depression Rating Scale (HAM-D), 21-item version. 21 All raters were trained to administer the scales; the results were assessed for inter-rater reliability.…”

Section: Methodsmentioning

confidence: 99%

Homocysteine and other markers of cardiovascular risk during a manic episode in patients with bipolar disorder

Chiarani

Tramontina

Ceresér

et al. 2013

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

Objective: To evaluate serum levels of different biomarkers associated with cardiovascular disease in patients with bipolar disorder (BD). Patients were prospectively evaluated in two separate instances: during acute mania and after remission of manic symptoms. All measurements were compared with those of healthy controls. Methods: The study included 30 patients with BD and 30 healthy controls, matched for gender and age. Biochemical parameters evaluated included homocysteine (Hcy), folic acid, vitamin B12, ferritin, creatine kinase (CK) and C-reactive protein (CRP). Results: Hcy levels were significantly higher in the BD patients, both during mania and after achieving euthymia. When Hcy was adjusted for body mass index, there was no significant difference between patients and controls. Ferritin was the only marker that showed a significant decrease during mania when compared to both euthymic patients and controls. There were no significant differences for folate, vitamin B12, CK and CRP. Conclusions: These findings do not show an association between alterations of markers of cardiovascular risk during manic episodes. Further studies are necessary to determine factors and mechanisms associated with cardiovascular risk in patients with BD.

show abstract

Section: Methodsmentioning

confidence: 99%

Homocysteine and other markers of cardiovascular risk during a manic episode in patients with bipolar disorder

Chiarani

Tramontina

Ceresér

et al. 2013

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Negative fi ndings with regard to venlafaxine [ 17 ] emerged in other studies, while mirtazapine's eff ects on serum BDNF have never been studied. Most treatment studies did not specifi cally consider treatment response as a potential factor for BDNF regulation or studied only treatment responders [ 18 -21 ] , while others found increasing serum BDNF in female responders to antidepressant treatment only [ 22 ] or no association with treatment response at all [ 17 , 23 ] . Taken together, the eff ect of antidepressants on serum BDNF is undisputed, while it is unclear whether all classes of antidepressants aff ect…”

Section: Changes Of Serum Concentrations Of Brain-derived Neurotrophimentioning

confidence: 99%

Changes of Serum Concentrations of Brain-Derived Neurotrophic Factor (BDNF) during Treatment with Venlafaxine and Mirtazapine: Role of Medication and Response to Treatment

et al. 2012

View full text Add to dashboard Cite

Introduction: Depression, stress and antidepressant treatment have been found to modulate the expression of brain-derived neurotrophic factor (BDNF). Recent research suggests that serum BDNF concentration is reduced in depression and that antidepressant treatment leads to an increase in serum BDNF concentration. Methods: We studied depressed patients receiving a randomized antidepressant treatment with either mirtazapine (n=29) or venlafaxine (n=27) for 28 days in a prospective design. Changes in the concentrations of serum neurotrophins in response to antidepressant treatment were assessed. Results: There was a significant ?treatment? by ?medication? interaction effect on BDNF serum concentrations that indicated a decline of BDNF in venlafaxine-treated patients (7.82?3.75?7.18?5.64?ng/mL), while there was an increase in mirtazapine-treated patients (7.64?6.23?8.50?5.37?ng/mL). There was a trend for a ?treatment? by ?remission? interaction with a favourable clinical course being related to increasing serum BDNF. Discussion: Changes in BDNF serum concentrations as a result of antidepressant therapy depend on the antidepressant and potentially on the clinical course.

show abstract

“…Sensitivity Analysis -Serum BDNF and Depression Status Study Recalculated P value Table 4 Sensitivity Analysis -Serum BDNF and Antidepressant Treatment Study Recalculated P value Huang (47) 0.002 Piccinni (19) 0.013 Yoshimura (18) 0.019 Aydemir -A (45) 0.016 Gervasoni (44) 0.013 Gonul (48) 0.029 Aydemir -B (46) 0.002 Hellweg (50) 0.004…”

mentioning

confidence: 99%

Serum Brain-Derived Neurotrophic Factor, Depression, and Antidepressant Medications: Meta-Analyses and Implications

Sen

Duman

Sanacora

2008

Biological Psychiatry

1,091

715

View full text Add to dashboard Cite

show abstract

Serum brain-derived neurotrophic factor levels in patients with major depression: Effects of antidepressants

Cited by 143 publications

References 48 publications

Homocysteine and other markers of cardiovascular risk during a manic episode in patients with bipolar disorder

Homocysteine and other markers of cardiovascular risk during a manic episode in patients with bipolar disorder

Changes of Serum Concentrations of Brain-Derived Neurotrophic Factor (BDNF) during Treatment with Venlafaxine and Mirtazapine: Role of Medication and Response to Treatment

Serum Brain-Derived Neurotrophic Factor, Depression, and Antidepressant Medications: Meta-Analyses and Implications

Contact Info

Product

Resources

About